BETHESDA, Md., Sept. 9, 2026 /PRNewswire/ -- AGNC Investment Corp. (Nasdaq: AGNC) ("AGNC" or the "Company") announced today that its Board of Directors has declared cash dividends on the outstanding depositary shares1 of the following series of preferred stock for the third quarter 2026:

Series of Preferred Stock

Ticker

Per Annum Dividend Rate

Dividend Per Depositary Share1

7.00% Series C Fixed-to-Floating Rate

AGNCN

9.16547%2

$0.58557

6.875% Series D Fixed-to-Floating Rate

AGNCM

8.38647%3

$0.53580

6.50% Series E Fixed-to-Floating Rate

AGNCO

9.04747%4

$0.57803

6.125% Series F Fixed-to-Floating Rate

AGNCP

8.75147%5

$0.55912

7.750% Series G Fixed-Rate Reset

AGNCL

7.750%6

$0.48438

8.750% Series H Fixed-Rate

AGNCZ

8.750 %

$0.54688

1.

Each depositary share represents a 1/1,000th interest in a share of preferred stock.

2.

The Series C Depositary Shares accrue dividends at a floating rate equal to Three-Month CME Term SOFR plus 0.26161% plus 5.111% per annum. The dividend rate for the dividend period ending October 14, 2026 is 9.16547% per annum.

3.

The Series D Depositary Shares accrue dividends at a floating rate equal to Three-Month CME Term SOFR plus 0.26161% plus 4.332% per annum. The dividend rate for the dividend period ending October 14, 2026 is 8.38647% per annum.

4.

The Series E Depositary Shares accrue dividends at a floating rate equal to Three-Month CME Term SOFR plus 0.26161% plus 4.993% per annum. The dividend rate for the dividend period ending October 14, 2026 is 9.04747% per annum.

5.

The Series F Depositary Shares accrue dividends at a floating rate equal to Three-Month CME Term SOFR plus 0.26161% plus 4.697% per annum. The dividend rate for the dividend period ending October 14, 2026 is 8.75147% per annum.

6.

The Series G Depositary Shares will accrue dividends from and including the original issue date to (but excluding) October 15, 2027 at a fixed rate of 7.75% per annum. From and including October 15, 2027, the dividend rate will reset during each reset period at a fixed rate equal to the five year U.S. Treasury Rate plus a spread of 4.39% per annum.

The dividend for each series of outstanding preferred stock is payable on October 15, 2026 to holders of record as of October 1, 2026.

For further information or questions, please contact Investor Relations at (301) 968-9300 or [email protected].

ABOUT AGNC INVESTMENT CORP. Founded in 2008, AGNC Investment Corp. (Nasdaq: AGNC) is a leading investor in Agency residential mortgage-backed securities (Agency MBS), which benefit from a guarantee against credit losses by Fannie Mae, Freddie Mac, or Ginnie Mae. We invest on a leveraged basis, financing our Agency MBS assets primarily through repurchase agreements, and utilize dynamic risk management strategies intended to protect the value of our portfolio from interest rate and other market risks.

AGNC has a track record of providing favorable long-term returns for our stockholders through substantial monthly dividend income, with over $16 billion of common stock dividends paid since inception. Our business is a significant source of private capital for the U.S. residential housing market, and our team has extensive experience managing mortgage assets across market cycles. To learn more about The Premier Agency Residential Mortgage REIT, please visit www.AGNC.com, follow us on LinkedIn and X, and sign up for Investor Alerts.

Share this article

Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app

SECAUCUS, N.J., Sept. 9, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.

"By embedding the Quest lab testing experience within the Apple Health app, we are making testing simpler, smarter and more available to people who want to connect biomarker and biometric insights to own their health," said Richard Adams, Senior Vice President and General Manager, Consumer, Quest Diagnostics. "This integration will help bridge the gap between clinical and consumer health and serve the growing interest in preventive health and wellness."

The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function. The panel also includes biometric readings that measure blood pressure, height, weight, and waist and hip circumferences, which may provide additional insights into metabolic health.

Users can purchase and schedule their blood draw and biometric readings at one of Quest's approximately 2,000 patient service centers in the United States for $119.

Shortly after testing, lab results will appear within the Apple Health app. Quest collaborates with third-party providers to review and approve all test orders and, at the user's request, discuss test results and next steps for no additional charge.

Chronic health conditions, such as heart disease and diabetes, affect as many as three in four American adults, yet can often be prevented if acted upon in early stages, according to the U.S. Centers for Disease Control and Prevention. Biomarker laboratory testing can identify early, asymptomatic signals of several chronic conditions, empowering individuals to make behavioral changes to reduce disease risk.

About Quest Diagnostics

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com 

1.Not available in all U.S. states.

SOURCE Quest Diagnostics

Share this article

THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, YouTube and Threads.

CONTACT: Amgen, Thousand Oaks

Elissa Snook, 609-251-1407 (media) 

Casey Capparelli, 805-447-1746 (investors)  

SOURCE Amgen

Share this article

Seismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime in Patients With Cardiogenic Shock

Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe and South America

Global Phase 3 program, Rescue HF CS, builds upon four completed Phase 2 trials in which more than 340 patients received istaroxime

DURHAM, N.C., Sept. 9, 2026 /PRNewswire/ -- Seismic Pharmaceuticals, a biotechnology company dedicated to advancing novel treatments for heart failure, today announced the commencement of its global Phase 3 clinical trial evaluating Istaroxime in patients with cardiogenic shock. The trial, entitled Rescue HF CS, will recruit patients from around the globe and is designed to become the first ever drug approved to treat the life threatening condition of Cardiogenic Shock.

The approximately 600-patient study will be conducted at clinical sites across the United States, Europe and South America. The trial is designed to build upon the successful clinical results generated through four previously completed Phase 2 trials in which more than 340 patients received Istaroxime.

Cardiogenic shock is a life-threatening condition that occurs when the heart is unable to pump enough blood to meet the body's needs, resulting in inadequate blood flow and oxygen delivery to vital organs. It may occur as a complication of acute heart failure, a severe heart attack or other serious cardiac conditions. Despite advances in critical care and mechanical circulatory support, cardiogenic shock continues to be associated with high rates of complications and mortality, underscoring the urgent need for new therapeutic options. Furthermore, there are no currently FDA approved treatments for the condition.

Istaroxime is a novel, first-in-class therapy being developed to improve cardiac function and hemodynamic stability in patients with cardiogenic shock. Unlike conventional inotropic therapies, Istaroxime has a unique dual mechanism of action designed to improve both systolic contraction and diastolic relaxation.

"The commencement of this global Phase 3 trial represents an important milestone for Seismic Pharmaceuticals and for the development of Istaroxime," said Gad Cotter, CEO and Chairman of the Board. "Cardiogenic shock remains a life-threatening condition with a significant need for new treatment options. This study builds upon the clinical experience generated in more than 340 patients across four Phase 2 trials, and we look forward to working with investigators and clinical sites throughout the United States, Europe and South America to advance this program."

The Phase 3 trial, Rescue HF CS, is expected to enroll approximately 600 patients with cardiogenic shock. Additional information regarding the trial's design, eligibility criteria and participating clinical sites will be available at ClinicalTrials.gov and other applicable clinical-trial registries.

About Istaroxime

Istaroxime is a novel, first-in-class investigational therapy being developed for the treatment of cardiogenic shock and acute heart failure. Istaroxime is designed to improve cardiac function through a dual mechanism of action that increases myocardial contractility while supporting myocardial relaxation. More than 340 patients have received Istaroxime across four previously completed Phase 2 clinical trials.

About Seismic Pharmaceuticals

Seismic Pharmaceuticals is a biotechnology company dedicated to advancing novel treatments for heart failure. The company combines deep therapeutic expertise with a proven track record in acute heart failure drug development. Seismic Pharma's founding portfolio of drug candidates was acquired from Windtree Therapeutics and is being advanced through clinical development with the support of a board of directors with extensive experience in successful heart-failure programs. The company is headquartered in Durham, North Carolina.

Media Contact

Gad Cotter

Seismic Pharmaceuticals

[email protected] 

SOURCE Seismic Pharmaceuticals

Share this article

COLUMBUS, Ohio, Sept. 9, 2026 /PRNewswire/ -- Huntington Bancshares Incorporated (Nasdaq: HBAN) will participate in the 2026 Barclays Global Financial Conference on Wednesday, September 16, 2026. Steve Steinour, chairman and chief executive officer, and Zach Wasserman, chief financial officer, are scheduled to present to analysts and investors at 7:30 AM (Eastern Time). They will discuss business trends, financial performance, and strategic initiatives. The presentation will include forward-looking statements.

Webcast Information

Interested investors may access the live audio webcast in the investor relations section of Huntington's website (www.huntington-ir.com). A replay of the webcast will be archived on the website.

About Huntington

Huntington Bancshares Incorporated is a $284 billion asset regional bank holding company headquartered in Columbus, Ohio. A top 10 U.S. commercial bank, The Huntington National Bank and its affiliates provide consumers, small and middle-market businesses, corporations, municipalities, and other organizations with a comprehensive suite of banking, payments, wealth management, and risk management products and services. Founded in 1866, Huntington operates over 1,400 branches in 21 states, with certain businesses operating nationally. Visit Huntington.com for more information.

SOURCE Huntington Bancshares Incorporated

Share this article

Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million

HENDERSON, Nev., Sept. 9, 2026 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading AI-powered research workflow platform, reported financial results for its fourth quarter and full fiscal year ended June 30, 2026.

Fiscal Fourth Quarter 2026 Summary (compared to prior-year quarter)

- Total gross profit of $6.4 million improved the Company’s gross margin percentage 200 basis points versus the prior year quarter to 53% driven by the continued Platform mix shift.

- B2B ARR grew $2.0 million or 14.1% compared to the fourth quarter of fiscal 2025 resulting in $16.2 million of ARR. This included AI related ARR of $0.8 million which grew 125% sequentially from the third quarter of fiscal 2026.

- Net income of $666,000, or $0.02 per diluted share, compared to $2.4 million or $0.07 per diluted share. The prior year included a $1.1 million favorable adjustment for the finalization of the Scite earnout.

- Adjusted EBITDA of $1.4 million and Adjusted EBITDA margin of 11.8%.

- Total revenue of $12.1 million, compared to $12.4 million in the prior year.

- Cash flow from operations of $1.8 million, compared to $2.3 million on the timing of working capital payments.

Fiscal Year 2026 Summary (compared to Fiscal 2025)

- Gross profit up 3.6% to $25.1 million. Total gross margin improved 260 basis points to 51.9% with the continued Platform mix shift as the main catalyst. Platforms revenue was 43% of total revenue compared to 39% in the prior year.

- B2B ARR grew $2.0 million or 14.1% versus the year ago period to $16.2 million. This included incremental AI related ARR of $0.8 million.

- Net income of $2.8 million, or $0.09 per diluted share, compared to $1.3 million, or $0.04 per diluted share. The prior-year results included $1.7 million of net other expense related to the Scite earn-out.

- Platform revenue up approximately 10% to $20.8 million. Annual Recurring Revenue (“ARR”) up 7.8% to $22.5 million, which includes approximately $16.2 million of B2B recurring revenue and $6.3 million of B2C recurring revenue.

- Adjusted EBITDA of $5.8 million, a Company record, compared to $5.3 million.

- Total revenue of $48.3 million, compared to $49.1 million.

- Cash flow from operations of $5.3 million compared to $7.0 million on the timing of working capital payments. The Company ended the fiscal year with $12.6 million in cash and cash equivalents.

“We launched multiple products in fiscal 2026, including new AI based products. Two of the AI products, Scite MCP and Article Galaxy MCP, allow researchers to utilize the unique functionality of Scite and Article Galaxy inside ChatGPT, Claude, Copilot, and any AI tools researchers already use. This is part of our strategy to support our users where they work and has resulted in us building a large pipeline of AI related revenue opportunities in FY27." said Roy W. Olivier, President and CEO of Research Solutions. "Platform revenue grew to 43% of total revenue, up from 39% in fiscal 2025. That mix shift expanded gross margin and helped us more than double net income for the full year in a challenging market. With a strong cash position and Adjusted EBITDA posture, we're well-positioned to continue investing in internally developed tools and to pursue strategic M&A that complements our current offerings.”

Fiscal Fourth Quarter 2026 Results

Total revenue was $12.1 million, compared to $12.4 million in the year-ago quarter, as increased platform revenue was more than offset by a decrease in transaction revenue.

Platform subscription revenue for the quarter was $5.3 million, compared to $5.2 million in the prior-year period. The increase was driven by a 14% increase in B2B platform ARR, due to a mix of new logo generation and upsell and cross-sells into the existing customer base, partially offset by a decline in B2C ARR.

The quarter ended with ARR of $22.5 million, up 7.8% year-over-year as B2B ARR increases more than offset a modest decline in B2C ARR (see the Company’s definition of annual recurring revenue below).

Transaction revenue was $6.8 million, compared to $7.3 million in the fourth quarter of fiscal 2025. The decrease was due to lower paid order volume. The transaction active customer count for the quarter was 1,323, compared to 1,338 customers in the prior-year quarter (see the Company's definition of active customer accounts and transactions below).

Total gross margin improved 200 basis points from the prior-year quarter to 53.0%. The increase was primarily driven by the continued revenue mix shift to the higher-margin Platforms business, including the expansion of the gross margin for that business.

Total operating expenses were $5.6 million, compared to $5.1 million in the fourth quarter of 2025. The increase was primarily related to higher sales expenses and up front investments in AI that were partially offset by reduced general and administrative expense.

Other expense for the quarter was approximately $0.2 million compared to other income of $1.2 million in the fourth quarter of fiscal 2025. Prior year results included a $1.1 million favorable adjustment related to the final determination of the Scite earnout.

Net income in the fourth quarter was $666,000 or $0.02 per diluted share, compared to $2.4 million, or $0.07 per diluted share, in the prior-year quarter. Adjusted EBITDA was $1.4 million, compared to $1.6 million in the year-ago quarter (see definition and further discussion about the presentation of Adjusted EBITDA, a non-GAAP term, below).

Full-Year Fiscal 2026 Results

Total revenue was $48.3 million compared to $49.1 million in fiscal 2025.

Platform subscription revenue for fiscal 2026 was $20.8 million, a 9.8% year-over-year increase. The increase was primarily due to organic growth in the core B2B platforms, including 105 net new B2B platform deployments. The increase included incremental AI related ARR of $0.8 million.

Transaction revenue was $27.5 million, compared to $30.1 million in fiscal 2025. The decrease was due to lower paid order volume, particularly in the second and third quarters of fiscal 2026.

Total gross margin improved 260 basis points from the prior year to 51.9%. The increase was primarily driven by the continued revenue mix shift to the higher-margin Platforms business.

Total operating expenses for the year were $21.5 million, compared to $21.7 million in fiscal 2025. The decrease was primarily related to reduced general and administrative and stock compensation expenses, partially offset by higher sales and marketing expenses.

Net income for fiscal 2026 was $2.8 million, or $0.09 per diluted share, compared to $1.3 million, or $0.04 per diluted share, in the prior year. Adjusted EBITDA was $5.8 million, compared to $5.3 million in fiscal 2025 (see definition and further discussion about the presentation of Adjusted EBITDA, a non-GAAP term, below).

Conference Call

Research Solutions President and CEO Roy W. Olivier and CFO David Kutil will host the conference call, followed by a question-and-answer period.

Date: Wednesday, September 9, 2026

Time: 5:00 p.m. ET (2:00 p.m. PT)

Dial-in number: 1-203-518-9708

Conference ID: RESEARCH

The conference call will be broadcast live and available for replay until October 9, 2026, by dialing 1-412-317-6671 and using the replay ID 11160802, and via the investor relations section of the Company's website at http://researchsolutions.investorroom.com/.

Fiscal Fourth Quarter and Full Year Financial and Operational Summary Tables vs. Prior-Year Quarter and Full Prior-Year

Active Customer Accounts, Transactions and Annual Recurring Revenue

The Company defines active customer accounts as the sum of the total quantity of customers per month for each month in the period divided by the respective number of months in the period. The quantity of customers per month is defined as customers with at least one transaction during the month.

A transaction is an order for a unit of copyrighted content fulfilled or managed in the Platform.

The Company defines annual recurring revenue ("ARR") as the value of contracted Platform subscription recurring revenue normalized to a one-year period. For B2C ARR, this includes the annualized value of monthly subscriptions, meaning their monthly value multiplied by twelve.

Use of Non-GAAP Measure – Adjusted EBITDA

Research Solutions' management evaluates and makes operating decisions using various financial metrics. In addition to the Company's GAAP results, management also considers the non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP measure provides useful information about the Company's operating results.

The tables below provide a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure. Adjusted EBITDA is defined as net income (loss), plus interest expense, other (income) expense, foreign currency transaction (gain) loss, provision for income taxes, depreciation and amortization, stock-based compensation, and other potential adjustments that may arise. Set forth below is a reconciliation of Adjusted EBITDA to net income (loss):

About Research Solutions

Research Solutions, Inc. (NASDAQ: RSSS) is a vertical SaaS and AI Company that simplifies research workflow for academic institutions, life science companies, and research organizations worldwide. As one of the only publisher-independent marketplaces for scientific, technical, and medical (STM) content, the Company uniquely combines AI-powered tools—including an intelligent research assistant and full-text search capabilities—with seamless access to both open access and paywalled research. The platform enables organizations to discover, access, manage and analyze scientific literature more efficiently, accelerating the pace of scientific discovery. For more information and details, please visit www.researchsolutions.com.

Partnership Will Help Clients Scale Mission-Ready AI

RESTON, Va., Sept. 9, 2026 /PRNewswire/ -- ICF (NASDAQ: ICFI), a leading global solutions and technology provider, today announced it has been named an OpenAI Select Partner, recognizing its proven ability to help organizations responsibly adopt and scale advanced AI services and solutions.

"Organizations need a practical path that integrates and operationalizes AI with their data, people, workflows and mission priorities, in a scalable, secure, well-governed way," said Kyle Tuberson, ICF chief technology officer. "Through this new partnership, ICF will combine OpenAI's frontier AI models with our leading mission, technology and implementation expertise to help government and commercial organizations accelerate innovation, improve operations and deliver measurable impact."

"ICF brings deep mission expertise and a strong track record of helping government agencies modernize critical programs," said Asad Zia, OpenAI director of public sector partner management. "By combining that experience with OpenAI's advanced AI capabilities, we can help public-sector organizations responsibly deploy AI to improve services, strengthen operations and deliver better outcomes for the people they serve."

ICF will apply OpenAI's technology to AI-enabled applications that improve citizen and customer experiences; AI-assisted software development and modernization that enhance client delivery; and internal enterprise use cases for operational efficiency. Across these efforts, ICF will apply its governance, risk management and human-centered implementation capabilities to help organizations determine where large language models can deliver the greatest value.

The collaboration builds on ICF's broader AI strategy and technology partner ecosystem, which brings together leading technologies, mission expertise and enhanced delivery capabilities to help clients speed up modernization efforts and improve service delivery.

As a trusted partner to public-sector and commercial clients and a leader in AI solutions, ICF helps organizations turn AI ambition into results. From strategy to execution, ICF supports clients in reducing time-to-value, accelerating mission impact and transforming service delivery through AI.

About ICF

ICF is a leading global solutions and technology provider. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at icf.com. 

Caution Concerning Forward-looking Statements

Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, as amended. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to: the government contracting industry generally; our dependence on contracts with U.S. federal, state and local, and international government clients for the majority of our revenue; failure by Congress or other governmental bodies to approve budgets and appropriations in a timely fashion, reductions in government spending, and the impact of a lengthy federal government shutdown; the current Administration's policy changes, executive orders, and failure to spend Congressionally mandated appropriations, including the resulting effect on government audits and contract terminations; changes in federal government budgeting and spending priorities; our ability to estimate and control costs under our fixed-price contracts; the realization of our backlog; the dependence of our commercial work on sectors of the global economy that are highly cyclical; and our ability to acquire and successfully integrate businesses. These and other factors that could cause our actual results to differ materially from those indicated in our forward-looking statements are described in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent filings with the Securities and Exchange Commission. The forward-looking statements included herein are made only as of the date hereof, and we specifically disclaim any obligation to update these statements in the future.  

Contact: Lauren Dyke, [email protected], +1.571.373.5577

SOURCE ICF

Share this article

Historic New York celebration honors a century of cultural exchange and the global influence of Chinese fashion

PORTAGE, Mich., Sept. 9, 2026 /PRNewswire/ -- Zhang Financial is proud to announce that CEO Lynn Chen-Zhang, CPA, PFS™, CFP®, served as a Co-Chair of the China Institute of America Centennial Grand Fashion Gala, held September 8, 2026, at The Pierre in New York City.

Celebrating the China Institute's 100th anniversary, the gala brought together prominent leaders in fashion, art, culture and philanthropy to recognize Chinese creativity and its growing influence around the world. The evening was chaired by renowned television personality, entrepreneur and cultural ambassador Yue-Sai Kan, with Lynn Chen-Zhang serving as Gala Co-Chair. Internationally acclaimed designers Guo Pei and Vera Wang participated as Gala Ambassadors.

Featured designers included Jason Wu, Vivienne Tam, Grace Chen and Laurence Xu, among others. The evening also honored Fern Mallis, widely recognized as the creator of New York Fashion Week, as well as other influential figures from the international fashion community.

"For one hundred years, the China Institute of America has served as an important bridge between cultures—advancing understanding, celebrating artistry and creating lasting connections," said Lynn Chen-Zhang. "It was a tremendous honor to help lead this historic celebration and to support an institution whose mission is especially meaningful at this moment in history."

In her welcome message to gala guests, Chen-Zhang reflected on fashion as a universal language that transcends national borders and allows individuals to express their heritage, identity and personal stories. She also emphasized that Chinese and American identities can be expressed in many different ways, united by creativity and mutual respect.

Zhang Financial supported the Centennial Grand Fashion Gala and congratulated the China Institute of America on this extraordinary milestone.

"Lynn's leadership reflects the values we share at Zhang Financial: excellence, cultural understanding and service to the broader community," said Charles Zhang, Founder and President of Zhang Financial. "We are proud to support the China Institute as it begins its second century of building meaningful connections between the United States and China."

About the China Institute of America

Founded in 1926, the China Institute of America is one of the oldest educational and cultural organizations in the United States dedicated to advancing a deeper understanding of China through programs in culture, art, education and business.

About Zhang Financial

Zhang Financial is an independent, NAPFA-registered Fee-Only wealth management firm providing objective investment management and financial-planning services to individuals, families and institutions. Headquartered in Portage, Michigan, the firm also maintains offices in Chicago, Detroit, Grand Rapids and Naples.

Charles Zhang was ranked No. 1 in the nation on Barron's 2025 Top 100 Independent Advisors, the highest-ranked Fee-Only advisor on the list.

Released on 9/15/25, based on a 12-month period ending 6/30/25. Zhang Financial paid no fee to be considered for or included in the ranking. The firm pays Barron's a licensing fee to use the ranking and related logo. Please visit zhangfinancial.com/disclosure for full ranking criteria and methodology.

Media Contact

Zhang Financial

Elizabeth Edgerton

[email protected]

269-385-5888

Zhangfinancial.com

SOURCE Zhang Financial

Share this article

Spigen Unveils Next-Generation Protection for Apple's iPhone 18 Lineup and First-Ever Foldable iPhone

IRVINE, Calif., Sept. 9, 2026 /PRNewswire/ -- Spigen is ready for the next generation of iPhone. Following Apple's latest launch, including the first foldable iPhone, Spigen unveiled a collection of cases and accessories designed to protect the iPhone 18 Pro and iPhone Duo without compromising style.

With nearly 20 years of experience protecting mobile devices and more than seven years developing protection for foldable devices, Spigen brings decades of design expertise to Apple's most innovative iPhones yet.

Apple's first foldable iPhone introduces new protection challenges, particularly around its hinge. Drawing from years of hands-on foldable development and testing, Spigen created a collection engineered specifically for the unique demands of the device.

- Slim Armor Pro S MagFit: Spigen's most popular foldable case returns with a 360° rotating magnetic kickstand and SecuLink technology, securely connecting the case panels while keeping the hinge protected.

- Ultra Hybrid MagFit: A crystal-clear case featuring Air Cushion Technology for edge-to-edge protection that keeps Apple's original design on display.

- Nano Pop MagFit: A soft, minimalistic silicone case featuring textured side grips for added comfort and secure hold, available in colorful designs to make the Duo pop.

iPhone 18 Pro & Pro Max Collection

For users looking to protect Apple's latest flagship iPhone, Spigen offers several styles designed around different user preferences.

- For the everyday minimalist: The Ultra Hybrid MagFit delivers crystal-clear protection with a polycarbonate back and TPU bumper, while the Nano Pop MagFit pairs a soft-touch silicone finish with textured side grips for a secure hold.

- For the design enthusiast: Ultra Hybrid Neo One features a 3D, tech-inspired design showcasing the components beneath the surface, while Spigen's new retro-printed C-One cases draws inspiration from the iMac G3 with its iconic translucent look.

- For someone who wants a premium feel: Enzo Aramid T uses lightweight aramid fiber for slim, weightless protection, while Spigen's Tough Armor T combines XRD foam with Air Cushion Technology for military-grade drop protection.

Spigen's latest Apple collection extends beyond cases:

- AluminaCore EZ Fit Screen Protector: First introduced last year, the AluminaCore EZ Fit Screen Protector is engineered to be slimmer, clearer, and significantly more durable, delivering 3× the strength of standard tempered glass.

- Classic LS for AirPods Pro: A protective case inspired by the iconic Apple Macintosh mouse, featuring a retro locking mechanism designed to mimic the classic "mouse click."

- WBF0 Apple Watch Band: A soft, lightweight fabric band designed for all-day comfort, featuring a secure hook-and-loop fastener and subtle blue stitch and patch design accents.

Availability

Spigen's newest collection offers a case for every way of using Apple's latest devices. Shop Spigen's iPhone 18 Pro, iPhone 18 Pro Max, and iPhone Duo collection on Amazon.

About Spigen

Spigen has been a trusted name in mobile accessories since 2008, committed to delivering innovative products that enhance the mobile experience. To learn more, please visit Spigen.com.

Media Contact

Kate Cho

949-502-5121

[email protected]

SOURCE Spigen Inc.

Share this article

Former Lancia Consult and Morgan Stanley executive joins to scale international operations and platform capabilities

SINGAPORE, Sept. 9, 2026 /PRNewswire/ -- YYForce Inc. (NASDAQ: YFOR) ("YYForce" or the "Company"), an AI-enabled workforce management platform and integrated facility management (IFM) provider operating across Asia and beyond, announced the appointment of Andrew Davison as Chief Strategic Officer (CSO), effective September 14, 2026. In his new role, Mr. Davison will spearhead YYForce's corporate strategy, direct portfolio governance, and oversee operational scaling initiatives to support the company's next phase of market expansion across international markets.

Mr. Davison brings over 20 years of executive leadership experience spanning the APAC, EMEA, UK, and US markets, specializing in commercial strategy, scaling high-performing teams, financial management, margin and risk control, and complex cross-functional delivery.

Prior to joining YYForce, Mr. Davison served as Director and Head of Transformational Delivery (APAC) at Lancia Consult in Singapore, where he directed regional delivery performance, portfolio health, and capability building to scale the business across multiple markets. During his tenure, he established the firm's Jakarta presence, designed regional delivery operating models, and provided executive-level operational due diligence and investment evaluation for private equity and corporate clients.

His extensive professional background also includes senior advisory and consulting roles as a Senior Principal Consultant at Slalom Consulting in London, where he led enterprise digital enablement and multi-market change strategies, and as a Principal Financial Services Transformation Consultant at BCS Consulting, where he managed large-scale regulatory remediation, risk management programs, and operational transformations for global financial institutions such as HSBC, Credit Suisse, and Morgan Stanley. He began his career managing institutional client relationships and trading operations at Morgan Stanley. Mr. Davison holds a BCom (Hons) in Business Studies and Economics from the University of Edinburgh and has completed executive training in Strategic Leadership with AI & ML at Singapore Management University.

"We are thrilled to welcome Andrew to the executive leadership team at YYForce," said Mike Fu, CEO of YYForce. "Andrew's exceptional track record in scaling organizations, driving rigorous commercial discipline, and executing complex operational transformations makes him the ideal leader to guide our strategic initiatives as we continue to scale our operations and maximize stakeholder value."

"I am excited to join YYForce at such a pivotal stage of growth," said Andrew Davison, Chief Strategic Officer of YYForce. "The company has demonstrated remarkable agility and innovation in its markets. I look forward to partnering with the leadership team to sharpen our strategic roadmap, optimize operational execution, and drive sustainable, long-term value for our clients, partners, and shareholders."

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is an AI-enabled workforce management platform and IFM provider, headquartered in Singapore and operating across Asia and beyond. The Company's intelligent workforce solutions platform, YY Circle, helps clients across hospitality, food and beverage, retail, and other service sectors predict, plan, and optimize workforce deployment. In YYForce's IFM business, its 24IFM software platform and comprehensive IFM subsidiary portfolio support clients across hospitality, transportation, banking, retail, and mixed-use facilities.

As both business lines scale, the Company is systematically embedding AI and automation capabilities – progressing from intelligent decision support toward increasingly autonomous workforce management – to improve service quality, reduce deployment costs, and drive long-term margin expansion. Listed on the Nasdaq Capital Market, YYForce is committed to infrastructure innovation, measurable client outcomes, and long-term value creation.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company bases these forward-looking statements on its expectations and projections about future events, which the Company derives from the information currently available to it. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. These factors include, but are not limited to, the Company's goals and strategies; the Company's future business development, financial condition and results of operations, including the introduction of new products and services, expected changes in the Company's revenues, costs and expenditures, anticipated customer growth, and demand for and market acceptance of the Company's products and services; and industry, market and regulatory conditions, including competition, government policies and regulations affecting the Company's industry, and other factors that may affect the Company's financial condition, liquidity and results of operations. For a more detailed discussion of risk factors, please refer to the Company's filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's most recent annual report on Form 20-F, as amended.

Investor Contact

Jason Zhi Yong Phua, Chief Financial Officer

YYForce

[email protected]

Media Contact

Amber Smoke

The Piacente Group, Inc.

[email protected]

SOURCE YYForce Inc.

Share this article